Elite Pharmaceuticals Inc. (ELTP) Financials Nov 2
Post# of 250665
Posted On: 11/20/2014 8:18:32 PM
Elite Pharmaceuticals Inc. (ELTP) Financials Nov 20, 2014, 4:00 p.m.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Elite Pharmaceuticals Inc.
Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 3.34M 4.27M 2.42M 3.4M 4.6M
Cost of Goods Sold (COGS) incl. D&A 2.52M 2.85M 1.22M 2.43M 3.74M
COGS excluding D&A 2.01M 2.37M 735,771 2.01M 3.24M
Depreciation & Amortization Expense 508,610 483,473 484,151 423,340 500,906
Depreciation - - 484,151 423,340 486,726
Amortization of Intangibles - - 0 0 14,180
Gross Income 824,541 1.42M 1.2M 971,451 864,364
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 2.76M 2.3M 3.17M 2.53M 6.15M
Research & Development 794,433 1.39M 1.74M 975,250 3.96M
Other SG&A 1.97M 918,030 1.43M 1.56M 2.19M
Other Operating Expense 0 0 0 0 0
Unusual Expense 4.08M 11.21M 12.67M (3.53M) 90.7M
EBIT after Unusual Expense (4.08M) (11.21M) (12.67M) 3.53M (90.7M)
Non Operating Income/Expense (512,912) (292,213) (249,999) (437,500) 19,831
Non-Operating Interest Income 1,064 - 0 0 0
Equity in Affiliates (Pretax) 0 0 - - -
Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Gross Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Interest Capitalized 0 0 - - 0
Pretax Income (8.06M) (13.88M) (15.54M) 1.13M (96.87M)
Income Tax 0 (301,413) (483,952) (353,718) (292,611)
Income Tax - Current Domestic 0 - (483,952) (353,718) (292,611)
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) - 0 (109,015) 0 0
Consolidated Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Minority Interest Expense 0 0 0 0 0
Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
EPS (Basic) (0.11) (0.14) (0.06) 0.00 (0.21)
Basic Shares Outstanding 75.58M 100.02M 259.16M 349.08M 463.02M
EPS (Diluted) (0.11) (0.14) (0.06) () (0.21)
Diluted Shares Outstanding 75.58M 100.02M 259.16M 526.88M 463.02M
EBITDA (1.43M) (402,287) (1.48M) (1.14M) (4.78M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Elite Pharmaceuticals Inc.
Fiscal year is April-March. All values USD millions. 2010 2011 2012 2013 2014 5-year trend
Sales/Revenue 3.34M 4.27M 2.42M 3.4M 4.6M
Cost of Goods Sold (COGS) incl. D&A 2.52M 2.85M 1.22M 2.43M 3.74M
COGS excluding D&A 2.01M 2.37M 735,771 2.01M 3.24M
Depreciation & Amortization Expense 508,610 483,473 484,151 423,340 500,906
Depreciation - - 484,151 423,340 486,726
Amortization of Intangibles - - 0 0 14,180
Gross Income 824,541 1.42M 1.2M 971,451 864,364
2010 2011 2012 2013 2014 5-year trend
SG&A Expense 2.76M 2.3M 3.17M 2.53M 6.15M
Research & Development 794,433 1.39M 1.74M 975,250 3.96M
Other SG&A 1.97M 918,030 1.43M 1.56M 2.19M
Other Operating Expense 0 0 0 0 0
Unusual Expense 4.08M 11.21M 12.67M (3.53M) 90.7M
EBIT after Unusual Expense (4.08M) (11.21M) (12.67M) 3.53M (90.7M)
Non Operating Income/Expense (512,912) (292,213) (249,999) (437,500) 19,831
Non-Operating Interest Income 1,064 - 0 0 0
Equity in Affiliates (Pretax) 0 0 - - -
Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Gross Interest Expense 1.53M 1.49M 654,057 392,964 899,916
Interest Capitalized 0 0 - - 0
Pretax Income (8.06M) (13.88M) (15.54M) 1.13M (96.87M)
Income Tax 0 (301,413) (483,952) (353,718) (292,611)
Income Tax - Current Domestic 0 - (483,952) (353,718) (292,611)
Income Tax - Current Foreign 0 0 - - -
Income Tax - Deferred Domestic 0 0 0 0 0
Income Tax - Deferred Foreign 0 0 - - -
Income Tax Credits 0 0 0 0 0
Equity in Affiliates 0 0 0 0 -
Other After Tax Income (Expense) - 0 (109,015) 0 0
Consolidated Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Minority Interest Expense 0 0 0 0 0
Net Income (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Extraordinaries & Discontinued Operations 0 0 0 0 0
Extra Items & Gain/Loss Sale Of Assets 0 0 0 0 0
Cumulative Effect - Accounting Chg - - 0 0 0
Discontinued Operations 0 0 0 0 0
Net Income After Extraordinaries (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
Preferred Dividends 0 0 0 0 0
Net Income Available to Common (8.06M) (13.58M) (15.17M) 1.49M (96.58M)
EPS (Basic) (0.11) (0.14) (0.06) 0.00 (0.21)
Basic Shares Outstanding 75.58M 100.02M 259.16M 349.08M 463.02M
EPS (Diluted) (0.11) (0.14) (0.06) () (0.21)
Diluted Shares Outstanding 75.58M 100.02M 259.16M 526.88M 463.02M
EBITDA (1.43M) (402,287) (1.48M) (1.14M) (4.78M)
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.
(0)
(0)